Dark

Check out our API

CDXC
ChromaDex Corporation
stock NASDAQ

Inactive

Mar 18, 2025

7.87USD-0.882%(-0.07)541,871

Pre-market

0.00USD-100.000%(-7.94)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 25, 2022

06:35AM EST ChromaDex Announces Results Of New Pilot Clinical Trial Showing Anti-Inflammatory Effects Of Nicotinamide Riboside Supplementation Benzinga

Jan 20, 2022

06:35AM EST ChromaDex And Designs For Health Partner For New Product Development On Niagen Benzinga

Nov 3, 2021

05:34PM EDT Recap: ChromaDex Q3 Earnings Benzinga

05:24PM EDT ChromaDex Q3 EPS $(0.13) Misses $(0.09) Estimate, Sales $17.31M Beat $17.17M Estimate Benzinga

09:10AM EDT Earnings Scheduled For November 3, 2021 Benzinga

Oct 18, 2021

06:39AM EDT ChromaDex Publishes an Update on Nicotinamide Riboside in Children Benzinga

Oct 1, 2021

06:34AM EDT ChromaDex Reports Jury In California Found Elysium Health Breached Its Contract With ChromaDex; Elysium, Mark Morris Will Pay Co. ~$2.25M-$2.5M In Damages, Estimated Interest Benzinga

Sep 29, 2021

06:39AM EDT ChromaDex Partners With Sinopharm Xingsha For Cross-Border Sales Of Tru Niagen Into Mainland China Benzinga

Sep 20, 2021

06:35AM EDT ChromaDex Shares Preclinical Research Findings And Scientific Initiations From The ChromaDex External Research Program Benzinga

Sep 15, 2021

06:35AM EDT ChromaDex Continues To Defend Strong Intellectual Property Portfolio And Plans To Appeal Judge's Ruling In Patent Infringement Lawsuit Benzinga

Aug 20, 2021

01:42PM EDT Return on Capital Employed Insights for ChromaDex Benzinga

Aug 4, 2021

06:38AM EDT HC Wainwright & Co. Maintains Buy on ChromaDex, Raises Price Target to $12 Benzinga

Aug 3, 2021

04:35PM EDT ChromaDex Q2 EPS $(0.08), Inline, Sales $17.70M Beat $17.16M Estimate Benzinga

03:52AM EDT Earnings Scheduled For August 3, 2021 Benzinga

Jul 23, 2021

11:12AM EDT ChromaDex Option Alert: Aug 20 $12.5 Calls Sweep (26) above Ask!: 815 @ $0.445 vs 2258 OI; Earnings 8/3 After Close Ref=$9.48 Benzinga

Jun 28, 2021

01:39PM EDT ChromaDex Option Alert: Aug 20 $12.5 Calls Sweep (26) near the Ask: 387 @ $0.801 vs 2072 OI; Earnings 8/5 After Close [est] Ref=$10.08 Benzinga

Jun 24, 2021

09:37AM EDT ChromaDex Shares See Volume; Short Seller J Capital Issues Negative Note On Co Titled 'Unhealthy A Full Dose of Promotion' Benzinga

09:20AM EDT ChromaDex Shares See Volume; J Capital Issues Negative Note On Co Titled 'Unhealthy A Full Dose of Promotion' Benzinga

Jun 16, 2021

06:36AM EDT ChromaDex Highlights Research Findings From ChromaDex External Research Program Benzinga

Jun 7, 2021

09:42AM EDT ChromaDex Shares Jump on Tru Niagen's Launch In Walmart Stores Benzinga

08:24AM EDT ChromaDex Shares Up 11%; Hearing HC Wainwright Reiterates Buy Rating, Sets 12-Month Price Target Of $11 Benzinga

06:42AM EDT ChromaDex Highlights Launch Of Its Tru Niagen Product In 3,800 Walmart Stores In US Benzinga

Jun 4, 2021

12:10PM EDT EXCLUSIVE: Chromadex CEO Rings Nasdaq Closing Bell, Talks Walmart Product Launch Benzinga

May 17, 2021

08:40AM EDT ChromaDex CEO Robert Fried Purchases 10,000 Shares At $6.65 Benzinga

May 14, 2021

03:03PM EDT The Promise Of Longevity Science: 3 Small-Cap Companies With Anti-Aging Products Benzinga

May 13, 2021

11:52AM EDT From BZ Small Cap Event: ChromaDex CFO Highlights Co. Close To Achieving Positive Adj. EBITDA Excluding Total Legal Expense Benzinga

11:30AM EDT ChromaDex CEO and CFO Begin Presentation During Benzinga's Global Small Cap Event Benzinga

May 10, 2021

10:07AM EDT ChromaDex shares were trading higher after HC Wainwright & Co maintained its Buy rating on the stock. Benzinga

08:43AM EDT 10 Biggest Price Target Changes For Monday Benzinga

07:14AM EDT HC Wainwright & Co. Maintains Buy on ChromaDex, Lowers Price Target to $11 Benzinga

May 6, 2021

04:05PM EDT ChromaDex Q1 EPS $(0.12) Misses $(0.09) Estimate, Sales $14.70M Miss $16.68M Estimate Benzinga

04:17AM EDT Earnings Scheduled For May 6, 2021 Benzinga

May 4, 2021

06:35AM EDT Chromadex and Ro Partner for New Product Development; Agreement Provides Ro With Rights to Chromadex's Patented Nicotinamide Riboside Ingredient Niagen Benzinga

Apr 28, 2021

06:34AM EDT ChromaDex and Health & Happiness (H&H) Group Announce Supply Agreement for Niagen Benzinga

Mar 23, 2021

04:41PM EDT ChromaDex Files For ~3.846M Share Common Stock Offering By Selling Shareholders Benzinga

Mar 16, 2021

12:19PM EDT 10 Biggest Price Target Changes For Tuesday Benzinga

06:46AM EDT HC Wainwright & Co. Maintains Buy on ChromaDex, Raises Price Target to $16 Benzinga

Mar 10, 2021

04:21PM EST Recap: ChromaDex Q4 Earnings Benzinga

04:03PM EST ChromaDex Sees FY21 Sales Growth 'Steady' In Ecommerce Unit, Gross Margin Improvement To Be Slightly Better Than 60% Benzinga

04:02PM EST ChromaDex Q4 EPS $(0.10) Misses $(0.09) Estimate, Sales $15.40M Beat $15.36M Estimate Benzinga

03:10PM EST ChromaDex shares were trading higher after the company announced that it's Tru Niagen will be available in 3000 Walmart stores across the US beginning in June. Benzinga

08:19AM EST ChromaDex announces Its Tru Niagen Will Be Available In 3,000 Walmart Stores Across US Beginning In June Benzinga

04:04AM EST Earnings Scheduled For March 10, 2021 Benzinga

Mar 9, 2021

10:07AM EST Earnings Preview: ChromaDex Benzinga

Mar 2, 2021

10:35AM EST ChromaDex Granted U.S. Patent Titled 'B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof' Benzinga

Feb 24, 2021

06:34AM EST ChromaDex Announces New Phase 3 Clinical Study Finds Nutritional Protocol Including Nicotinamide Riboside Accelerates Recovery in Mild-to-Moderate COVID-19 Patients Benzinga

Feb 22, 2021

07:17AM EST ChromaDex Raises $25M Via Equity At 22% Discount Benzinga

06:31AM EST ChromaDex Announces $25M Private Placement of Common Stock with a New Institutional Investor Benzinga

Dec 9, 2020

11:34AM EST From BZ Small Cap Event: ChromaDex Highlighting Global Partnerships With AS Watson, Nestle Health Science Benzinga

11:27AM EST From BZ Small Cap Event: ChromaDex Discussing Co.'s Treatment For Nicotinamide Adenine Dinucleotide, Tru Niagen Benzinga

11:25AM EST ChromaDex CEO Rob Fried, CFO Kevin Farr Now Beginning Presentation At BZ Small Cap Event Benzinga

Dec 7, 2020

05:22PM EST Schedule Of NYSE-, Nasdaq-Listed Publicly-Traded Companies Presenting At Benzinga's Small Cap Conference Dec. 8-9 Benzinga

Nov 23, 2020

09:15AM EST UPDATE: ChromaDex Provided Response To FDA, FTC Letter, Said 'disagrees with the assertion in the Letter Co's products are intended to mitigate, prevent, treat, diagnose or cure COVID-19 in violation of certain sections of the FD&C, FTC Act' Benzinga

09:15AM EST ChromaDex 8-K Shows Co. Received Warning Letter From FDA, FTC, ' asserts Co.'s TRU NIAGEN products are intended to mitigate, prevent, treat, diagnose or cure COVID-19 in violation of certain sections of the Federal Food, Drug, and Cosmetic Act' Benzinga

Nov 9, 2020

06:39AM EST ChromaDex and Watsons Launch New TRU NIAGEN EX Stick Packs in Hong Kong, Expanding Product Line and Advancing Global Retail Partnership Benzinga

Nov 4, 2020

04:09PM EST ChromaDex Q3 EPS $(0.07) Beats $(0.10) Estimate, Sales $14.20M Miss $14.29M Estimate Benzinga

04:41AM EST Earnings Scheduled For November 4, 2020 Benzinga

Nov 3, 2020

10:09AM EST Preview: ChromaDex's Earnings Benzinga

Oct 19, 2020

06:35AM EDT ChromaDex Corp Announces New Study from NIH Finds Nicotinamide Riboside Helps Improve Telomere Dysfunction in Human Cells, Mice Benzinga

Oct 8, 2020

06:35AM EDT New Preclinical Study Finds Nicotinamide Riboside May Improve Immune Cell Function Benzinga

Oct 7, 2020

10:50AM EDT Shares of ChromaDex Corp. (CDXC) are gaining nearly 5% on Wednesday morning after the biotech company reported positive data from its COVID-19 Phase 2 study of nicotinamide riboside. RTTNews

Oct 6, 2020

10:04AM EDT ChromaDex Corp. Shares Move Higher; Hearing Oppenheimer Raises Price Target To Street High Of $9 Benzinga

06:44AM EDT ChromaDex Highlights Publicatoin Of Study Results Showing 'Nutritional Protocol Including Nicotinamide Riboside Plus Standard Of Care Reduces Recovery Time In COVID-19 Patients By Nearly 30%' Benzinga

Sep 9, 2020

06:34AM EDT ChromaDex Highlights Publication Of Study Showing Niagen 'Prevents Light-Induced Retinal Damage in Mice' Benzinga

Aug 18, 2020

06:36AM EDT ChromaDex Highlights Publication Of Human Trial On Niagen Benzinga

06:20AM EDT HC Wainwright & Co. Maintains Buy on ChromaDex, Raises Price Target to $7 Benzinga

Aug 6, 2020

04:11PM EDT ChromaDex Q2 EPS $(0.06) Beats $(0.10) Estimate, Sales $15.30M Beat $13.87M Estimate Benzinga

Jul 16, 2020

06:34AM EDT ChromaDex Highlights Results Of New Preclinical Study Published In 'Nature Scientific Reports' Probing Role Of Niagen In Addressing Social Deficits In Autism Spectrum Disorder Benzinga

Jul 14, 2020

06:33AM EDT ChromaDex External Research Program Signs 200th Material Transfer Agreement For Niagen Research Benzinga

Share